Friday, October 30, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 21, 2026

Netflix (NFLX) Q4 2025 Earnings Call Transcript

View original at nasdaq.com
Netflix (NFLX) Q4 2025 Earnings Call Transcript Image source: The Motley Fool. Date Tuesday, Jan. 20, 2026 at 4:45 p.m…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Netflix operates in 12 ad markets

    80% confidence
  • Netflix expects content amortization to increase 10% year-over-year in 2026

    80% confidence
  • Netflix historically expanded operating margin by approximately 2 percentage points annually on average

    80% confidence
  • Netflix primary quality metric reached all-time high in 2025

    80% confidence
  • There are 500+ million smart TV households globally that are non-Netflix members

    80% confidence
  • Netflix has less than 10% of TV time in all major markets

    80% confidence
  • Q2 2024 revenue growth was 17% reported

    80% confidence
  • Gaming market size is approximately $140 billion in consumer spend excluding China

    80% confidence
  • Q4 2025 churn improved year-over-year

    80% confidence
  • Netflix tested vertical video for approximately 6 months

    80% confidence
  • The Warner Bros. acquisition represents a tremendous, very achievable opportunity

    80% confidence
  • Live events represent a relatively small portion of total view hours

    80% confidence
  • Modular interactive video ads with dynamic templates completed testing in late 2025 with global rollout in 2026

    80% confidence
  • M&A expenses will create half a percentage point drag on operating margin in 2026

    80% confidence
  • Netflix forecasts 2026 revenue of $51 billion, representing 14% year-over-year growth

    80% confidence
  • Netflix ad revenue was 2.5x higher in 2025 compared to prior year

    80% confidence
  • Post-acquisition, 85% of Netflix revenue will come from current core businesses

    80% confidence
  • India ranked #2 and #3 for Netflix paid net adds and revenue growth in Q2 2024

    80% confidence
  • Customer satisfaction reached all-time high

    80% confidence
  • Theatrical distribution is a business decision that changes with conditions and insights, not a religious principle

    80% confidence
  • Warner Bros. global box office exceeds $4 billion

    80% confidence
  • Netflix executed 200+ live events

    80% confidence
  • Netflix will maintain 45-day theatrical window post-Warner Bros. acquisition

    80% confidence
  • Netflix has approximately 7% of addressable consumer and ad spend globally

    80% confidence
  • Netflix will spend $17 billion on content cash in 2026, growing slower than revenue

    80% confidence
  • Sign-up flow optimization generated material revenue wins in Q2 2024

    80% confidence
  • Branded originals viewing grew 9% year-over-year in H2 2025 and 7% in H1 2025, representing approximately 50% of total viewing

    80% confidence
  • Q2 2024 had strong acquisition and healthy retention across all regions

    80% confidence
  • Netflix content cash-to-expense ratio is 1.1x

    80% confidence
  • YouTube surpassed BBC monthly average audience in the UK according to Barb

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com
Netflix (NFLX) Q4 2025 Earnings Call Transcript — Source | Via News | Finance Via News